Cell and Gene Therapy
05.06.19 | 15:00 – 15:30 Uhr
Executing the logistics of cell and gene therapies is a challenge like no other—after all, if you cannot deliver the therapy to the patient, its efficacy is irrelevant, as the patient receives no benefit. For your patients, the stakes have never been higher. As your logistics partner, our record of flawless execution has never been more valuable. Discover how to partner with World Courier and access our global logistics platform.
Because cell and gene therapies involve living cells there can be extremely limited shelf lives, so timely transport is, quite plainly, a matter of life or death. Collaborative assessment and study design are just the beginning. We partner with key stakeholders in study-specific SOPs, extensive contingency planning and transparency to ensure unexpected complications don’t impact your delivery. Some might call it excessive. We call it reliability your research and patients can trust.
As cell and gene therapies move through clinical trials and advance toward a commercial launch, innovators must overcome unprecedented challenges. In many cases, this will require redefining established approaches within many areas of commercialization. Together with industry-leading partners across the AmerisourceBergen enterprise, we offer end-to-end commercialization strategies for making this new, patient-centered logistics model scalable.
In the world of cell and gene therapy transport, success requires diverse, reliable solutions. A single treatment might require both controlled-ambient and cryogenically-frozen shipments within the same supply loop. With empirically-backed expertise in all conditions for shipping, we can build a robust and flexible partnership with your clinical and commercial operations team to create truly customized temperature-controlled shipping solutions that help patients access life-changing treatment.
Dieser Vortrag ist Bestandteil des Programmblocks "Arzneimittellogistik" mit den weiteren Themen:
Erste Erfahrungen bei der Umsetzung der EU-Fälschungsrichtlinie
Herr Prof.Dr. Martin J. Hug, Universitätsklinikum Freiburg
Clinical Trial Logistics / Direct to Patient
Frau Pia Schmidt, Client Relationship Director, PAREXEL International